Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq
April 01 2019 - 4:30PM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that it received notice
from The Nasdaq Stock Market LLC indicating that the Company
regained compliance with the minimum bid price requirement in
Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price
of the Company’s common stock being $1.00 per share or greater for
the 10 consecutive business day period from March 18, 2019 to March
29, 2019 and that the previously reported non-compliance listing
matter is now closed.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
sexual health, vaginal health, fertility, and contraception. The
company’s mission is to identify, develop and bring to market a
portfolio of novel, differentiated therapies that expand treatment
options, improve outcomes and facilitate convenience for women in
the areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential first-in-class
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive vaginal ring; Sildenafil Cream, 3.6%, a novel
cream formulation of sildenafil to treat female sexual arousal
disorder utilizing the active ingredient in Viagra®; DARE-BV1, a
unique hydrogel formulation of clindamycin phosphate 2% to treat
bacterial vaginosis via a single application; and DARE-HRT1, a
combination bio-identical estradiol and progesterone intravaginal
ring for hormone replacement therapy following menopause. To learn
more about Daré’s full portfolio of women’s health product
candidates, and mission to deliver novel therapies for women,
please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use
these channels to distribute material information about the
company, and may also use social media to communicate important
information about the company, its finances, product candidates,
clinical trials and other matters. The information Daré posts
on its investor relations website or through social media channels
may be deemed to be material information. Daré encourages
investors, the media, and others interested in the company to
review the information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Alex GrayBurns McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda GuisbondCanale
Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024